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Previously, we have proposed mupirocin-in-liposomes-in-hydrogel delivery system as advanced delivery system with the potential
in treatment of burns. In the current studies, we evaluated the system for its cytotoxicity, ability to prevent biofilm formation, act
on the mature biofilms, and finally determined its potential as wound treatment in in vivomice burn model. The system was found
to be nontoxic against HaCaT cells, that is, keratinocytes. It was safe for use and exhibited antibiofilm activity against S. aureus
biofilms, although the activity was more significant against planktonic bacteria and prior to biofilm formation than against mature
biofilms as shown in the resazurin and the crystal violet assays. An in vivo mice burn model was used to evaluate the biological
potential of the system and the healing of burns observed over 28 days. The in vivo data suggest that the delivery system enhances
wound healing and is equally potent as the marketed product of mupirocin. Histological examination showed no difference in the
quality of the healed scar tissue, whereas the healing time for the new delivery system was shorter as compared to the marketed
product. Further animal studies and development of more sophisticated in vivomodel are needed for complete evaluation.
1. Introduction
Burn wound healing is a complex process characterized by
challenges in wound management, treatment, and healing in
terms of scarring [1]. Although the improvements in burn
care increased the survival of burned patients, they also
resulted in prolonged hospital stays [2]. One of the recent
focuses of improved wound therapy, including burn therapy,
is the use of antimicrobials, not only to prevent the wound
infection, but also to act on biofilms [3, 4]. At the same time,
topical antimicrobial formulations need to be nontoxic and
nonirritant to the skin.
In previous studies we developed and characterized the
mupirocin-in-liposomes-in-hydrogel system destined for
burns therapy [5]. Chitosan, which is the basic vehicle in our
delivery system, is known to exhibit very low toxicity
potential in humans. Mupirocin is an effective and safe
antimicrobial used in topical wound treatment [6].The safety
of mupirocin-in-liposomes destined for skin application was
tested in this study.
Many bacteria that are known to colonize wounds,
including burns, are also known to be able to form biofilms,
such as Staphylococcus aureus and Pseudomonas aeruginosa
[7]. Biofilms are 3D-aggregates characterized by an increased
resistance to antimicrobial, immunological, and chemical
attack, making their eradication a challenge [8]. Wounds are
typically subject to exogenous and endogenous microbial
contamination, particularly pronounced by the presence of
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maturing bacterial biofilms in the wound. A typical challenge
of these infections is the presence of the extracellular poly-
meric material (commonly referred to as matrix or EPS) that
encases the cells, creating a physical barrier that makes access
to the cellular core more difficult and contributing to the
overall stability and persistence of the biofilms. The presence
of wound biofilm may further inhibit downregulation of the
immune responses causing systemic debilitation [9–11].
Topical antimicrobials are an appealing choice for the
treatment of burnwound infections, due to a decreased risk of
systemic toxicities and the ability to deliver the antimicrobials
directly to the site of action.They are employed for both pro-
phylaxis and treatment of burn wound infections despite no
established susceptibility breakpoints.Mupirocin is known to
be effective against suspended gram positive bacteria, includ-
ing MRSA [2]. Additionally, antibiofilm effects of mupirocin
against S. aureushave been reported [12].The aimof thiswork
was to examine the effect of mupirocin, formulated in lipo-
somes, against S. aureus biofilms. We hypothesized that lipo-
somes could enhance the antibiofilm activity of mupirocin by
increasing its penetrability into biofilms through the EPS and
probably even deeper into the biofilms, while at the same time
reducing its effects on the planktonic bacteria, thus poten-
tiating the antibiofilm selectivity of mupirocin. Antibiofilm
drugs with lower effects on planktonic bacteria are particu-
larly promising, as they can potentially lower the likelihood
of bacterial resistance development.
The final efficacy evaluation of any wound dressing needs
to be performed in an appropriate animal model. As our
focus was the potential of mupirocin in wound treatment,
we selected the mice burn model and compared the efficacy
of our system against marketed mupirocin-containing prod-
uct, Bactroban, a commercially available product used for
topical treatment of burn wounds. According to producer
recommendations, Bactroban is to be applied on the wound
three times a day. Our delivery system has shown to provide
sustained release [5] and can thus lessen the number of appli-
cations per day,which results in reducednursing time and less
discomfort to the patient due to the dressing changes [13].The
tested delivery system is based on chitosan hydrogel as vehicle
and our aim was, in addition, to confirm that chitosan itself
has the wound healing potential, which would act in synergy
with antimicrobial and liposomes in the system.
2. Materials and Methods
Mupirocin calcium dehydrate micronized (MC) was kindly
provided by Pliva (Zagreb, Croatia). High MW chitosan
(Brookfield viscosity 800.00 cps and degree of deacetylation
of 77%) was a product of SigmaAldrich Chemistry (St. Louis,
MO, USA). Lipoid S 100 was a gift from Lipoid GmbH (Lud-
wigshafen, Germany). Glycerol and acetic acid were obtained
from Merck KGaA (Darmstadt, Germany). Propylene glycol
was purchased from the Norwegian Medical Depot (Oslo,
Norway). Bactroban creme (2%, w/w) was the product of
GlaxoSmithKline (Barnard Castle, Great Britain).
2.1. Preparation and Characterization of Liposomes. Lipo-
somes were prepared according to the dry film method as
described previously [5]. In a round bottom flask, mupirocin
(30mg) and phospholipid (200mg) were dissolved in meth-
anol (∼20mL). The solvent was then removed by vacuum
on a rotary evaporator (Bu¨chi R-124, Bu¨chi Labortechnik,
Flawil, Switzerland). The drug-lipid film was rehydrated
by 10mL of distilled water (pH 6.8) and hand shaken for
10min. The liposome dispersion was left in the refrigerator
overnight before removal of unentrappedmupirocin by ultra-
centrifugation (25min at 10∘C and 32000 rpm Beckmann-
L8-70M ultracentrifuge, Beckmann instruments Inc., Palo
Alto, CA, USA). The pellet was then resuspended in 10mL
of distilled water; liposomes that were destined for hydrogel
formulations were resuspended in 5mL of distilled water.
For calculating the entrapment efficiency of mupirocin
in liposomes, mupirocin concentration in both pellet and
supernatant was measured by high performance liquid chro-
matography according to the method described in Hurler
et al. [5]. In brief, a reversed phase column (XTerra RP
18
5 𝜇m, 3.9 × 150mm2 column, Waters, Dublin, Ireland) was
used in combination with a mobile phase that consisted of
acetonitrile and ammonium acetate (0.05M) in the ratio
of 27.4 : 72.5 (v/v), and pH value was adjusted to 6.3 with
hydrochloric acid.The flow rate was set to 1mL/min, column
temperaturewas 30∘C, and sample temperaturewas 25∘C.The
samples (injection volume of 20 𝜇L) were run for 9min, at
detection wavelength of 228 nm.
The liposomal suspensions showed an entrapment effi-
ciency of 62.4% (±8.8%) and a mupirocin concentration
in liposomal suspension of 1.87mg/mL. Liposomal suspen-
sions for hydrogel preparations had accordingly a mupirocin
concentration of 3.74mg/mL, as resuspension medium was
reduced to half. Liposomes were multilamellar in structure
and rather polydisperse (PI of 0.570), with an average
diameter of 920 nm, as determined by photon correlation
spectroscopy [5].
2.2. Preparation of Chitosan Hydrogel and Liposomes-in-
Hydrogel. Chitosan hydrogel was prepared as described ear-
lier [15]. In brief, high molecular weight chitosan (2.5%,
w/w) was dissolved in a blend of glycerol (10%, w/w) and
acidic acid (2.5%, w/w), respectively. The gel was left at room
temperature for 48 h before further treatment.
For liposomes-in-hydrogel formulations, 10% (w/w) of
liposomal dispersion was manually mixed into chitosan
hydrogel until even distribution. The resulting mupirocin
concentration was at 374 𝜇g/mL formulation.
2.3. Cell Viability Testing. Cell viability was tested according
to the modified method by Kempf et al. [16] and Louis and
Siegel [17]. HaCaT cells were seeded in 24-well plates and
solutions of free mupirocin and mupirocin-in-liposomes (1,
5, 10, 50, and 100 𝜇g/mL, resp.) were added. DMSO, which
was used as solvent for mupirocin and empty liposomes
served as controls. Plainmedium served as a negative control.
After 24 h of incubation at 37∘C and 5% CO
2
, the cells were
washed with RPMI medium to remove the dead cells. The
remaining cells were trypsinated and, after 2min at 37∘C,
washed again with medium. The cell suspension with trypan
blue was incubated for 2min at 37∘C and afterwards counted
in a haemocytometer.Thedead cells appeared blue due to dye,
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whereas the viable cells remained unstained.The cell viability
was calculated by subtracting the amount of dead cells from
the total number of cells andwas expressed as percentage.The
results were set into a relation with the negative control. All
tests were performed in triplicate.
2.4. Biofilms
2.4.1. Bacterial Growth in Planktonic and Biofilms. The bio-
film-producing strain Staphylococcus aureus (ATCC 25923)
was used as a model bacterium. Bacteria were cultured in
tryptic soy broth (TSB) (Fluka Biochemika, Switzerland)
under aerobic conditions at 37∘C and 200 rpm to reach
exponential growth (108 CFU/mL). The planktonic trials
were performed by adding exponentially grown bacteria
(106 CFU/mL) into sterile, flat-bottomed, 96-polystyrene
microtiter well plates (Nunclon Δ surface; Nunc, Denmark)
together with the samples and incubated during 18 h at 37∘C,
similar time as the one used for the biofilm formation. The
absorbance was automatically measured at 620 nm every
15min using a Varioskan multimode plate reader (with the
aid of a kinetic loop) and an automatic plate shaking step
(240 rpm, 5 s) was performed prior to each absorbance mea-
surements. Endpoint measurements obtained after 18 hours
were used for the potency calculations. To promote biofilm
formation, the exponentially grown bacterial suspension
(106 CFU/mL, 200𝜇L/well) was added into sterile 96-poly-
styrene microtiter well plates and the plates were incubated
for 18 h under aerobic conditions (37∘C, 200 rpm). During the
preventive antibiofilm screenings, compounds were added at
the same time as the bacterial suspension into the wells. To
measure the effects on themature biofilms, they were allowed
to form first for 18 h, and then the planktonic solution in each
well was replaced with fresh TSB containing the compound,
followed by incubation for additional 24 h (37∘C, 200 rpm).
2.4.2. Sample Preparation. The following samples were test-
ed: (i) empty liposomes (20mg/mL lipid content in distilled
water, coded as EL) used as controls, (ii) liposomes loaded
with mupirocin (20mg/mL lipid, 1.729mg/mL mupirocin
calcium dehydrate, in distilled water, coded as LM), and (iii)
free mupirocin in propylene glycol (1.729mg/mL mupirocin
calcium dehydrate, in propylene glycol 10% (w/w), coded
as M). The samples were let to stand at room temperature
for 30min before starting the trials. To ensure complete
homogenization, the samples were sonicated in a high power
ultrasonic bath (Bandelin Sonorex Digitec) at RT (5min,
35 kHz). Compound concentrations were within the range
0.01–70𝜇M for the prior-to-exposure trials and within the
range 1–405 𝜇M for the postexposure trials. Penicillin G was
used as a positive control in both the biofilms and planktonic
trials. A stock solution of penicillin G (20mM) was freshly
prepared before the trials in a Mueller-Hinton media.
2.4.3. Biofilm Quantification Assays. For measuring the pres-
ence of viable cells and the total biomass in the wells, the
resazurin staining and crystal violet were used, respectively,
using the protocols that have been described earlier [18,
19]. Briefly, the biofilms were first stained with 20𝜇M
resazurin for 20min (200 rpm, in room temperature, RT),
and fluorescence was measured at 𝜆excitation = 560 nm and
𝜆emission = 590 nm using a Varioskanmultimode plate reader.
Immediately after, the resazurin stain was removed and
replaced by crystal violet.The biofilms were stained for 5min
(RT) using a Combi multidrop dispenser then washed two
timeswithmilli Q-water using aBiomek 3000 liquid handling
workstation. The remaining dye was then solubilized in 96%
ethanol and absorbance (𝜆 = 595 nm) was measured using a
Varioskan multimode plate reader.
2.4.4. Data Processing. Potencies (as expressed through half-
inhibitory concentrations, IC
50
values) were determined by a
nonlinear regression curve fitting (with variable slope) using
GraphPad software, Prism 5.0c for Mac OS X, USA (2011).
At least 8 concentrations were included in the potency trials,
and each concentration was tested with 8 replicates in 3
independent trials.The performance of the antibiofilm assays
was evaluated using typical statistical parameters (𝑍󸀠, 𝑆/𝐵 and
𝑆/𝑁).Their calculationsweremadewith the aid of the control
samples (untreated biofilms and media control samples).The
parameters were calculated as in [18].
2.5. In Vivo Experiment
2.5.1. Animals. The aim of in vivo study was to evaluate the
effectiveness of themupirocin-in-liposomes-in-hydrogel sys-
tem as wound dressing as well as compare its effectiveness for
amarketed product. Prior to the experiment, 7-week-old CD1
male mice (𝑛 = 35) were purchased from Charles River Lab-
oratories, Sulzberg, Germany. The animals were randomly
divided into five groups each receiving different treatment:
(I) Bactroban 2%, (II) liposomal mupirocin, (III) chitosan
hydrogel, (IV)mupirocin-in-liposomes-in-hydrogel, and (V)
no treatment, respectively. The mice were kept in individual
filter-top cages and were allowed feed and water ad libitum
during the one week of acclimatization and throughout
the experiment. The study was approved by the Norwegian
National Animal Research Committee; all experiments were
performed according to the recommendations of the Feder-
ation of European Laboratory Animal Science Associations
and the Norwegian legislation on care and use of experimen-
tal animals. The mice were housed in the same room at 21∘C
and 55% relative humidity under a 12 h day/-night cycle.
2.5.2. Burn Wounds. Each mouse was weighed for the health
monitoring reasons before it was anaesthetized by 2% isoflu-
rane gas (mask) and received a subcutaneous injection of
Temgesic (0.3mg/kg) for analgesia. The animal was shaved
at its dorsal side with an electric razor and disinfected using
70% ethanol (v/v). The burn wound was induced by pressing
a cylindrical metal rod (0.79 cm2) that has been heated on
a warming plate for 30 s, to the shaved area for 30 s. This
procedure led to a burn wound of approximately 2% of body
surface. The wound was photographed for the measurement
of wound size reduction.
Animals received subcutaneous injected Temgesic
(0.3mg/kg) every 12 h for the first 48 h of the experiment;
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afterwards all mice received Metacam (5mg/kg) per os in
their drinking water for the additional four days.
2.5.3. Treatment of Wounds. As the treatment, 1 g of different
formulations was applied directly onto the burn wound.
Group I animals were treated with Bactroban 2% (𝑛 = 4);
Group II was treated with liposomal mupirocin (𝑛 = 5);
Group III with plain chitosan hydrogel (𝑛 = 4); Group IV
with mupirocin-in-liposome-in hydrogel (𝑛 = 6), and Group
V served as control group (𝑛 = 4) and did not receive any
treatment.
The first treatmentwas applied right after induction of the
burnwound. During the first week after burn induction,mice
received treatment once daily; in the remaining three weeks
the treatment was applied every second day.
2.5.4. Evaluation of Burn Wound. The size of the wound was
measured at days 4, 8, 12, 16, 20, 24, and 28 after the burn
induction.
On day 28, the animals were sacrificed and histological
samples were taken from the healed wound site and from the
normal skin (dorsum) and fixed in 4% paraformaldehyde in
PBS with 0.02M sucrose, pH 7.4. The tissue samples were
embedded in paraffin wax, processed, sectioned (3–5 𝜇m),
and stained with hematoxylin and eosin (H&E), or with the
van Gieson technique for connective tissue staining.
2.5.5. Analysis of Data. All data are presented as the mean ±
standard deviation (SD). Data were analyzed by analysis of
variance repeated measures (rANOVA); a P value < 0.05
was regarded as significantly different. Tukey’s multiple-
comparison post hoc test was applied when applicable.
3. Results and Discussion
3.1. Cell Viability. Formulations that are destined for admin-
istration onto burn wounds have to fulfill several require-
ments.The primary one is that these formulations should not
be toxic to healthy skin cells. In this study we tested the cell
viability of HaCaT cells, that is, immortalized keratinocytes,
when exposed to either free mupirocin or mupirocin-in-
liposomes. Whereas it is know that mupirocin is nontoxic in
humans [6], liposomal mupirocin formulations have not
been, to the best of our knowledge, tested regarding their tox-
icity on the skin.
After exposure for 24 h [16], mupirocin both in the
free form and encapsulated in liposomes was found to be
noncytotoxic (0–10%) or moderately cytotoxic (>10–20%)
in the tested concentration range from 1 up to 100𝜇g/mL.
Neither DSMO, even in the highest concentration used, nor
empty liposomes exhibited any cytotoxic effect; the survival
rate of cells after 24 hwas 95%. Freemupirocin did not exhibit
any cytotoxic effect in any of the tested concentrations.
Mupirocin-in-liposomes showed a similar pattern with the
exceptions at the concentrations of 5 and 50 𝜇g/mL. How-
ever, as the cell survival at the highest tested concentration
(100 𝜇g/mL) was over 96%, the results observed that for those
two concentrations 5 and 50 𝜇g/mL (cell survival 81.5 and
86.6%, resp.) can only be explained by the failure in exper-
imental setup.
In this study we also showed that mupirocin-in-liposo-
mes exhibited no toxic effect on keratinocytes. Boyce et al.
[20] could not show significant growth inhibition of ker-
atinocytes and fibroblasts when exposing the cells to a
blending of neomycin (40 𝜇g/mL), polymyxin B (700U/mL),
andmupirocin (40 𝜇g/mL). Other agents that are widely used
inwounddressings, such as silver, can exhibit significant toxic
effect on both keratinocytes and fibroblasts [21]. Burd et al.
[21] tested various wound dressings containing silver for their
cell toxicity and reepithelialization and found that dressings
such as Acticoat and Contreet Foam exhibit significant toxic
effects on keratinocytes and fibroblasts that were isolated
from human skin. When tested in in vivo experiments
these dressings were reported to delay the reepithelialization.
However, cytotoxicity tests of Kempf and coauthors [16],
who used HaCaT cells instead of keratinocytes cultured from
excised human skin that Burd and colleagues [21] were using,
could not confirm the cytotoxic effect of Acticoat to the same
extent. These inconsistent findings indicate that the cell type
is influencing the cell viability properties.
3.2. Biofilm. The complexity of bacterial communities in
wounds has historically been underestimated and only
recently the presence and importance of biofilms in wound
healing has started to gain a wider recognition [22]. A biofilm
is a complex microbial community, built by the bacteria
embedded in a protective matrix of sugars and proteins.
Biofilms contribute to the persistent, chronic inflammatory
changes in the wound bed and are clearly linked to impaired
wound healing [9–11]. Although in vitro and in vivo models
of biofilms vary and remain to be subject for discussions,
the models intent to simulate the functional characteristics
of chronic pathogenic biofilms and can be sampled for
characterization and analysis of the experimental biofilms [8].
However, the current lack of adequate in vivo models and
their proper validation, limits the possibility ofmimicking the
wound, particularly burn, completely [22].
Mupirocin is known to be effective against suspended
gram positive bacteria, including MRSA. In our previous
study on antimicrobial activity of various mupirocin for-
mulations, such as free mupirocin, mupirocin-in-liposomes,
mupirocin-in-liposomes-in-hydrogel, and a marketed prod-
uct (Bactroban), we confirmed their activities against S.
aureus [5]. It is known that many bacteria are able to form
biofilms, including S. aureus, which is amongst the typical
bacterial species colonizing burn wounds [7, 23].
In this study the potential of mupirocin, both in the free
form and in liposomes, was tested for its ability to prevent or
counteract established S. aureus biofilms. Firstly, we showed
that free mupirocin (M) is indeed active against planktonic
S. aureus with potency values on the submicromolar range
(Table 1) and thus has a potential to prevent the creation of
biofilms.The mupirocin-in-liposomes (LM), in contrast, was
found to be 2.7 times less active, based on endpoint measure-
ments made after 18 hours of bacterial growing. In addition,
the LM sample was less effective in delaying the planktonic
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Table 1: Quantification of antibacterial and antibiofilm activity of mupirocin samples.
Sample
Biofilm bacteria
IC50, 𝜇M
(95% confidence intervals)
Planktonic bacteria
IC50, 𝜇M
(95% confidence intervals)
Prior to biofilm formation After biofilm formation Turbidity
Viability Viability
Mupirocin 0.27 (0.48–0.70) 50%a 0.20 (0.42–0.67)
Mupirocin-in-liposomes 0.58 (0.16–0.45) 50%a 0.53 (0.14–0.26)
Penicillin G 0.13 (0.12–0.14) 45.2%b 0.10 (0.08–0.13)
aPercentual inhibition at 405𝜇M.
bPercentual inhibition at 5mM. Penicillin G fails to cause more than 45.2% of inhibition of biofilms viability in the postexposure assay, as previously shown in
Skogman et al. [14].
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Figure 1: Kinetic curves of the effects of mupirocin samples on
planktonic growing of S. aureus. The effects of the mupirocin
samples are shown only at 0.1𝜇M for simplicity.
growing, as seen on the kinetic curves of planktonic growth
(Figure 1). These results support the view that the liposome
formulation was less available to interact with the bacteria,
resulting in a lower activity of the antibiotic on the suspended
bacteria. Empty liposomes, as expected, did not have any
effect on the planktonic growth.
The antibiofilm effects of the mupirocin samples were
then measured (Table 1). These results refer to the effects on
biofilms viability as measured using the resazurin reduction
assay. In brief, this assay is based on the use of a redox
dye (resazurin) which is converted to a fluorescent product,
resorufin, by the metabolically active bacteria residing on the
inner core of the biofilms. Both samples (M and LM) were
able to prevent biofilm formation, and the potency values in
both cases corresponded rather well with the potency deter-
mined in planktonic bacteria. In this exposure paradigm,
it is plausible to hypothesize that both M and LM interact
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Figure 2: Wound size reduction in in vivo healing experiments.
with planktonic bacteria and efficiently decrease the amount
of viable bacteria that can reach the surface and initiate
the biofilm formation process. Similar activity trends were
observed in the crystal violet assay, which indicated that
both M and LM had concomitant effects on the viability and
biomass of the biofilms.The biomass reduction is, in this case,
probably related to the decrease on the viable cell fraction of
the biofilms.
Measurements of mupirocin effects on the established
(18 h-formed) biofilms were then performed, but the regis-
tered antibiofilm activity did not exceed 50% for both M
and LM samples, thus hampering the estimations of their
potencies (as expressed by IC
50
values). For instance, in the
case of LM at 1 𝜇Mconcentration, a 40% inhibition of biofilm
viability in mature biofilms was seen, but the inhibition did
not increase over 50% even with as high concentrations as
405 𝜇M.This situation is similar to what has been previously
registered on biofilms exposed to penicillin (Table 1). In the
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Figure 3: Histological photographs of burn wounds, 28 days after induction. Sections are stained with hematoxylin and eosin. Scale bars:
1mm. Representative samples are shown from animals treated with (a) Bactroban, Group I; (b) mupirocin-in-liposomes, Group II; (c) plain
chitosan hydrogel, Group III; and (d) mupirocin-in-liposomes-in-hydrogel, Group IV. (e) shows a healed burn wound from a nontreated
mouse (Group V, control). Arrows point to epidermis, and (∗) indicates dermis in (a)–(e). Arrow heads in (b) and (c) point to the keratin
layer which often detached during tissue preparation.
case of penicillin-treated biofilms, we have earlier demon-
strated that a significant overproduction of the matrix takes
place, which could impede the access of penicillin to the
remaining metabolically active cells [14]. Alternatively, it
could be possible that in penicillin ormupirocin-insulted bio-
films a higher fraction of the cells could switch to a dormant
or less metabolically active state, in which they are less
sensitive to the effects of these antibiotics. In such scenario,
increasing the penetrability of the mupirocin by means of
the liposomes carriers would not influence the antibiofilm
activity, as we had initially hypothesized.
Another study has shown the reduction of S. aureus
(ATCC 25293) biofilm biomass with mupirocin in concen-
tration between 15 and 250𝜇M by 90% [12]. The discrepancy
between these results may be explained with the different
methodology that was used. In our study the mature biofilms
were allowed to grow for 18 h before the sample was added,
Ha et al. [12] let the biofilm grow for 8 days. It is known
that time also influences the susceptibility of biofilms against
antimicrobials and young biofilms (as the ones formed in
our in vitro model) may respond differently to the effects
of antibiotics when compared to older biofilms. In an in
vivo study, Roche et al. [24] have shown that mupirocin was
effective in partial-thickness wounds that were infected with
methicillin-resistant S. aureus (ATCC 33592). However it was
more effective when applied 4 h after the bacterial infection
as compared to the application 24 h after bacterial infection.
These findings support the results in our study and show the
importance of early treatment in order to avoid the formation
of biofilms on wounds. In addition, other studies confirmed
the antibiofilm effectiveness of mupirocin not only against S.
aureus, but also against P. aeruginosa [25] which is a bacterial
specie also typically found in wounds, colonizing the deeper
areas of the affected issue.
3.3. In Vivo Evaluation. In this study we evaluated different
mupirocin formulations in a mice burn wound model; for
this purpose burn wounds (1 cm in diameter) were induced
on the dorsal side of mice and treated for four weeks. The
change in wound size over time with according formulations
is displayed in Figure 2 (see also Supplementary Materials
available online at http://dx.doi.org/10.1155/2013/498485). On
day 28 after the induction of burn wounds the mice were
sacrificed and the scar tissue was evaluated histologically
(Figure 3).
All woundswere closed at latest after 28 days of treatment;
with mupirocin-in-liposomes-in-chitosan showing signifi-
cantly (𝑃 < 0.05, according to Tukey’s multiple-comparison
test) faster healing compared to the other groups. However,
one needs to consider that all groups, the group I, which
was treated with Bactroban, the group II (mupirocin-in-
liposomes), and the group III (plain chitosan hydrogel) had
similar healing time as compared to the control group V,
which did not receive any treatment. This would implement
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that the healing time of the wounds alone cannot be the
dominant indicatorwhen evaluating the quality of burn treat-
ment. We did not observe any signs of inflammation during
the tested period, which was also confirmed in histological
evaluation. We need to state that one of the reasons that we
failed to show the significance among the different treatment
efficiencies can be the reduced number of animals completing
the experiments (66%), as animals biting of the wounded site
were euthanized and excluded from the experiment. Male
mice tend to be more aggressive than female mice, and it may
therefore be a better option to use female mice.
The histological evaluations of the quality of the scar
tissue showed complete re-epithelialization of all wounds.
In all groups, the epidermis of the healed wounds was
typically thin, hairless, and without epidermal ridges, while
the underlying dermis contained a dense connective tissue
devoid of inflammation (Figure 3). In group III (plain chi-
tosan hydrogel, 𝑛 = 4), two animals showed increased
epidermal thickness and ridge formation in part of the
wound, covering areas in dermis with chronic inflammation
and calcification, which might be a result of itching and
scratching by the animals. One animal in group I (Bactroban,
𝑛 = 4) showed a complete recovery of hair follicles in the
healed wound (not shown). We have also realized that the
final histological evaluation was not sufficient to conduct
complete comparison and are planning to design further
studies in a different time frame, namely, performing the
histological evaluation at earlier time points, every seven
days.
Finally, the burn model we have used has several limita-
tions [26] and needs to be optimized prior to further studies.
The challenge of developing a suitable and reproducible
animal model for burns remains to be addressed [3] but these
methodological elements that we have discussed above could
be taken into account to help improving future in vivo studies
in this burn wounds model.
4. Conclusions
We have shown that the novel drug delivery system for
mupirocin,mupirocin-in-liposomes-in-hydrogel, is nontoxic
in skin cells, at least in the tested HaCaT cells. It exhibits the
potential to prevent the formation of S. aureus-based biofilms
which is of high relevance concerning the development of
wound dressings. Although we could not prove the supe-
riority of this system over the marketed product in in vivo
mice burn model, we have shown that the system is equally
good and safe for administration onto wounded site. More in
vivo evaluations are needed to define the systems’ potential as
wound dressing.
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